PML and acute promyelocytic leukemia: Beyond conventional JAK inhibitors, clinically validated small-molecule inhibitors targeting PML, such as Arsenic Trioxide (used successfully in acute promyelocytic leukemia) (62), warrant investigation for CD-associated fibrosis.